Imaging · Machine learning · Clinical trials

Advanced data analytics for clinical trials

QSA applies the latest imaging and machine learning technologies to show more precisely where treatments are working, across every stage of a clinical trial.

  • Phase 1 to 4 trials
  • ISO 9001:2015 certified (BSI)

Corpus callosum tractography

Services along the trial life cycle

From protocol design to post-trial analysis

Participants needed for 80% power in a trial in primary progressive MS, by MRI outcome and sequence: 3,180 with deep grey matter volume on T2-weighted scans, 420 with cortical grey matter on T2-weighted scans and 62 with lesion volume on FLAIR. One dot per participant. Numbers from Supplementary Table 5 of the paper. Adapted from Goebl et al., Nat Commun 2025 (opens in new tab) (CC BY 4.0)

01 · Pre-trial

Design trials that can detect change

  • Imaging protocol design and imaging charter
  • Power calculations and prognostic enrichment
  • Site selection, training and qualification
Pre-trial services
Four synthetic brain scans are checked on arrival. One passes and goes on to an expert read; three show ghosting, blurring and banding and are queried with the site. The audit trail then runs through receipt, completeness, quality control and expert read to the report. Synthetic MRI: MNI ICBM152 template (© L. Collins, MNI, McGill), simulated artefacts

02 · During trial

Run imaging with full auditability

  • Image receipt, completeness and quality control
  • Visual reads by trained experts, for efficacy and safety
  • Quality management (ISO 9001:2015)
During-trial services
Treatment effect on new gadolinium-enhancing lesions, treated versus control, in two types of MS found with SuStaIn from MRI and serum neurofilament light. Phase 2 trial: hazard ratio 0.13 (95% CI 0.05 to 0.38) in the early-sNfL type and 0.10 (0.02 to 0.44) in the late-sNfL type. Phase 3 trial: 0.48 (0.33 to 0.71) in early-sNfL and 0.27 (0.16 to 0.46) in late-sNfL. Numbers from Table 5 of the paper. Adapted from Willard et al., Brain 2025 (opens in new tab) (CC BY 4.0)

03 · Post-trial

Find where treatments work

  • Data-driven patient staging and subtyping
  • Machine-learning prognosis
  • Causal modelling and brain age
Post-trial services
Screenshot of the ARIAEducation.eu home page (opens ARIAEducation.eu in a new tab)

04 · Imaging education and consulting

Deepen imaging insights

Education and specialised studies

  • Continuing Professional Development courses
  • Online radiology training
ARIAEducation.eu (opens in new tab)
Axial MRI slice with grey- and white-matter segmentation outlines

Technology and biomarkers

Trial-grade tools, from image receipt to insight


  • Automated image QC

    Machine learning that flags image issues such as blurring, ghosting and banding.

  • QSlice

    Processing pipelines with integrated quality control and interactive scan viewing.

  • QViewer

    Expert review with multi-visit comparison, lesion annotation and safety reads.

  • QSAtrophy

    Objective measurement of brain volume percentage change.

  • MindGlide

    Deep learning for rapid brain-atrophy outcomes in phase 2 and 3 trials.

  • SuStaIn

    Data-driven disease subtypes, with each patient staged within them.

Conventional biomarkers

  • Lesion number and volume
  • Whole-brain and regional volume
  • Spinal cord area and change

Advanced MRI analytics

  • MTR, DTI and NODDI, QSM, MTV
  • Slowly expanding lesions
  • Functional MRI

AI-driven stratification

  • Subtyping and staging (SuStaIn)
  • Prediction of treatment response
  • Prognostic trial enrichment

Areas of work

Neurology and beyond

Evidence

Quality you can audit

ISO 9001
Quality management system certified to ISO 9001:2015 by BSI
Phase 1–4
The full range of imaging services for clinical trials
25+ yrs
Of UCL imaging methods applied to clinical trial data
  • 2024 · Global pharmaceutical company

    A multi-year MS subtyping study through image analysis.

  • 2025 · Cell therapy

    A three-year imaging analysis for an MS trial of a CAR-T cell therapy.

Planning a clinical trial?

Tell us about your study and the imaging questions behind it.